Stoke Therapeutics is a biotechnology company working to increase gene expression to treat a wide array of severe genetic diseases, including genetic conditions affecting the central nervous system, eye, and liver. Stoke was launched in 2018 with a $40 million Series A investment funded by Apple Tree Partners.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/04/18 | $40,000,000 | Series A |
Apple Tree Partners | undisclosed |
| 10/23/18 | $90,000,000 | Series B |
Alexandria Venture Investments Apple Tree Partners Cormorant Asset Management Janus Henderson Investors Perceptive Advisors RA Capital Management Redmile Group RTW Investments Sphera Funds Management | undisclosed |
